Amgen Announces Additional $300M U.S. Manufacturing Investment

Amgen invested an additional $300 million in U.S. manufacturing, bringing its total investment to nearly $2 billion over the last year. This move aims to boost the company's domestic manufacturing capacity.

Amgen announced an additional $300 million investment in its Juncos, Puerto Rico biologics manufacturing facility, bringing the company's total U.S. manufacturing commitments to nearly $2 billion over the past year. The Puerto Rico plant currently distributes medicines to more than 60 countries and is a cornerstone of AMGN's global supply chain for biologic therapies.

The latest investment adds to a series of domestic manufacturing pledges: $650 million previously announced for Puerto Rico, $900 million for Ohio, $600 million for a science and innovation center in California, and more than $1.5 billion in North Carolina. Amgen joins a wave of global drugmakers boosting U.S. production in response to the Trump administration's tariff proposals, which could reach 100% on imported branded medicines.

The strategic timing positions AMGN favorably ahead of any pharmaceutical tariff implementation. Domestic production capacity for biologics — which are complex to manufacture and difficult to quickly reshore — is increasingly seen as a competitive moat for companies that have invested early. Analysts expect Amgen's manufacturing scale to support pricing resilience and supply reliability as trade policy uncertainty continues.

Related Stocks

AMGN